Based on the available data, the forecast for respiratory system medicine sales in Japan from 2024 to 2028 shows a steady estimation of $7.1 per capita each year. This consistency indicates no expected fluctuation or growth in the market on a per capita basis during these years. Previously, the value in 2023 was actual, suggesting stability rather than growth. Year-on-year variations remain absent, evidencing a stagnant forecast.

Future trends to watch for:

Potential impact of emerging respiratory treatment technologies.
Changing demographics and aging population effects on demand.
Government healthcare policies influencing medication accessibility and pricing.